Proteome Sciences plc provided sales guidance for the 2013 and 2014. Revenue for 2013 is expected to show a significant increase over 2012, driven by increased demand for PS Biomarker Services, SysQuant® pilot studies, TMT® and the contract announced with Thermo Fisher Scientific. Sales lead times however have taken longer than anticipated and the timing and revenue from a number of other contracts expected in the fourth quarter has been delayed and is now projected to fall into 2014. The company's core activities are performing well and the company remains confident about prospects.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.21 GBX | 0.00% | 0.00% | -7.06% |
May. 16 | Proteome Sciences promises AGM return to growth in 2024 | AN |
May. 16 | AIM WINNERS & LOSERS: Proteome Sciences eyes return to growth in 2024 | AN |
1st Jan change | Capi. | |
---|---|---|
-7.06% | 15.76M | |
-5.81% | 180B | |
-1.63% | 106B | |
-4.14% | 67.55B | |
-6.56% | 46.11B | |
+13.22% | 45.79B | |
+2.58% | 41.61B | |
+19.93% | 31.07B | |
+11.40% | 24.77B | |
-5.36% | 24.27B |
- Stock Market
- Equities
- PRM Stock
- News Proteome Sciences plc
- Proteome Sciences plc Provides Sales Guidance for the 2013 and 2014